Chapter Thirteen - Medicine as Monopoly

CHAPTER THIRTEEN

Medicine as Monopoly

BAYER IS STILL known for aspirin.
But that’s just the gateway drug.

Behind the brand is a massive pharmaceutical portfolio of cancer drugs, antibiotics, birth control, blood thinners, hormone therapies, cardiovascular treatments, and more. Some are lifesaving. Some are routine. All are patented. All are priced to profit.

This is how modern medicine works.

Drug development is expensive. That’s the claim. Companies argue they need exclusive rights to recoup research costs and fund innovation. In practice, that means patents, lobbying, price hikes, and limited access. Especially in countries without universal healthcare.

Bayer is part of that system. So are the other pharmaceutical giants. But Bayer’s edge comes from how wide its reach goes. It controls not just production, but licensing, distribution, and in some cases, the only available version of a drug.

In the 2000s, Bayer faced legal challenges over agreements that delayed generic versions of Cipro, an antibiotic. In other cases, Bayer was accused of engaging in ‘pay-for-delay’ settlements that kept generics off the market.

The result?
Longer monopolies. Higher prices. Fewer choices.

It’s not illegal in most cases. It’s not hidden. It’s how the system is built. Innovation is packaged inside exclusivity. Treatment is tied to profit. And the companies that master the cycle don’t just survive, they dominate.

Medicine became a business.
Bayer made sure it stayed that way.